Ohm20,
Long story, but quite by accident, I found myself learning just a little bit about Guillain–Barré Syndrome.
And that led me to a number of research papers, including this one:
The Role of Chemokines in Guillain-Barré Syndrome
https://pubmed.ncbi.nlm.nih.gov/23447114/
Excerpt:
Does leronlimab maybe have potential application here -- or have you already rejected it?
Lastly, on a related topic, I wish CytoDyn had the bandwidth and resources to polish their slide deck -- not only to bring it up to the standards of similar stage biotechs -- but also to include a somewhat more comprehensive list of potential indications (without overreaching, of course).
If we are lucky, that slide deck will be viewed by tens of thousands of new potential investors. Discounting the retail segment for a moment, I think it's important for institutional and hedge fund investors to have a bigger picture of the leronlimab's market potential.
I've been half-thinking about taking a stab at it myself, but I don't really have the skillset to do it justice, and I'm not sure the company would be receptive to it (especially coming from an unrelated third party).
Long story, but quite by accident, I found myself learning just a little bit about Guillain–Barré Syndrome.
And that led me to a number of research papers, including this one:
The Role of Chemokines in Guillain-Barré Syndrome
https://pubmed.ncbi.nlm.nih.gov/23447114/
Excerpt:
And, finally, I tried to find your latest list of potential indications and observed that Guillain-Barré wasn't on it (maybe I don't have the latest list).Quote:Results: Although there were a few observational human and animal studies demonstrating chemokine ligand/receptor expression in GBS and EAN, in vitro and in vivo functional studies using gene knockouts, neutralizing antibodies, or small molecular antagonists were limited. CCL2-CCR2, CCL5-CCR5, and CXCL10-CXCR3 have been most strongly implicated in EAN and GBS pathogenesis, providing targets for molecular blockade
Does leronlimab maybe have potential application here -- or have you already rejected it?
Lastly, on a related topic, I wish CytoDyn had the bandwidth and resources to polish their slide deck -- not only to bring it up to the standards of similar stage biotechs -- but also to include a somewhat more comprehensive list of potential indications (without overreaching, of course).
If we are lucky, that slide deck will be viewed by tens of thousands of new potential investors. Discounting the retail segment for a moment, I think it's important for institutional and hedge fund investors to have a bigger picture of the leronlimab's market potential.
I've been half-thinking about taking a stab at it myself, but I don't really have the skillset to do it justice, and I'm not sure the company would be receptive to it (especially coming from an unrelated third party).
3
